OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer
Maria S. Asdourian, Nishi Shah, Ted V. Jacoby, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 8, pp. 933-933
Closed Access | Times Cited: 39
Maria S. Asdourian, Nishi Shah, Ted V. Jacoby, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 8, pp. 933-933
Closed Access | Times Cited: 39
Showing 1-25 of 39 citing articles:
Bullous pemphigoid
Hossein Akbarialiabad, Enno Schmidt, Aikaterini Patsatsi, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access | Times Cited: 1
Hossein Akbarialiabad, Enno Schmidt, Aikaterini Patsatsi, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access | Times Cited: 1
Checkpoint inhibitor‐induced bullous pemphigoid differs from spontaneous bullous pemphigoid
Norman C. Kramer, G. Müller, Sarah Zierold, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 8
Closed Access | Times Cited: 7
Norman C. Kramer, G. Müller, Sarah Zierold, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 8
Closed Access | Times Cited: 7
What's new in the pathogeneses and triggering factors of bullous pemphigoid
Hideyuki Ujiie
The Journal of Dermatology (2022) Vol. 50, Iss. 2, pp. 140-149
Open Access | Times Cited: 26
Hideyuki Ujiie
The Journal of Dermatology (2022) Vol. 50, Iss. 2, pp. 140-149
Open Access | Times Cited: 26
Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study
Anusuya Kawsar, Charlotte Edwards, Pooja Patel, et al.
British Journal of Dermatology (2022) Vol. 187, Iss. 6, pp. 981-987
Open Access | Times Cited: 24
Anusuya Kawsar, Charlotte Edwards, Pooja Patel, et al.
British Journal of Dermatology (2022) Vol. 187, Iss. 6, pp. 981-987
Open Access | Times Cited: 24
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases
Jolanta Pach, Kailyn Valido, Annika Belzer, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 4, pp. 595-607
Closed Access | Times Cited: 5
Jolanta Pach, Kailyn Valido, Annika Belzer, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 4, pp. 595-607
Closed Access | Times Cited: 5
Bullous Pemphigoid: A practical approach to diagnosis and management in the modern era
Camille M. Powers, Sach Thakker, Nicholas Gulati, et al.
Journal of the American Academy of Dermatology (2025)
Closed Access
Camille M. Powers, Sach Thakker, Nicholas Gulati, et al.
Journal of the American Academy of Dermatology (2025)
Closed Access
Exanthematische Arzneimittelreaktionen
Mirjana Ziemer, Elisabeth Livingstone
Deleted Journal (2025)
Closed Access
Mirjana Ziemer, Elisabeth Livingstone
Deleted Journal (2025)
Closed Access
Remote presentation of nivolumab-induced bullous pemphigoid in hepatocellular carcinoma
Ashley Yoo, Joyce Chen, Vivek Parameswara Sarma, et al.
BMJ Case Reports (2025) Vol. 18, Iss. 4, pp. e263285-e263285
Closed Access
Ashley Yoo, Joyce Chen, Vivek Parameswara Sarma, et al.
BMJ Case Reports (2025) Vol. 18, Iss. 4, pp. e263285-e263285
Closed Access
Risk of Autoimmune Skin Diseases Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis Using the FAERS Database
Zhiyong Dong, M. He, Y. Hu
Dermatologic Therapy (2025) Vol. 2025, Iss. 1
Open Access
Zhiyong Dong, M. He, Y. Hu
Dermatologic Therapy (2025) Vol. 2025, Iss. 1
Open Access
Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience
Martina Merli, Martina Accorinti, Maurizio Romagnuolo, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 12
Martina Merli, Martina Accorinti, Maurizio Romagnuolo, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 12
Ocular surface toxicities associated with modern anticancer therapies
R. C. Boucher, Oscar Haigh, Emmanuel Barreau, et al.
Survey of Ophthalmology (2023) Vol. 69, Iss. 2, pp. 198-210
Closed Access | Times Cited: 12
R. C. Boucher, Oscar Haigh, Emmanuel Barreau, et al.
Survey of Ophthalmology (2023) Vol. 69, Iss. 2, pp. 198-210
Closed Access | Times Cited: 12
Drug associated bullous pemphigoid: what's new?
Efthymia Soura, Maria Gerochristou, Τheodora Douvali, et al.
Italian Journal of Dermatology and Venereology (2025) Vol. 159, Iss. 6
Closed Access
Efthymia Soura, Maria Gerochristou, Τheodora Douvali, et al.
Italian Journal of Dermatology and Venereology (2025) Vol. 159, Iss. 6
Closed Access
Autoimmune pemphigus: difficulties in diagnosis and the molecular mechanisms underlying the disease
Olga Simionescu, Sorin Tudorache
Frontiers in Immunology (2025) Vol. 16
Open Access
Olga Simionescu, Sorin Tudorache
Frontiers in Immunology (2025) Vol. 16
Open Access
Dermatologic toxicities related to cancer immunotherapy
Yosra Vaez-Gharamaleki, Mohammad Amin Akbarzadeh, Farhad Jadidi‐Niaragh, et al.
Toxicology Reports (2025), pp. 102021-102021
Open Access
Yosra Vaez-Gharamaleki, Mohammad Amin Akbarzadeh, Farhad Jadidi‐Niaragh, et al.
Toxicology Reports (2025), pp. 102021-102021
Open Access
Precision Immunomodulation: Understanding and Harnessing Cytokine Pathways to Treat and Prevent Immune-Related Adverse Events (irAEs)
Matthew J. Hadfield, Ross D. Merkin, Sherin J. Rouhani, et al.
Best Practice & Research Clinical Haematology (2025), pp. 101625-101625
Closed Access
Matthew J. Hadfield, Ross D. Merkin, Sherin J. Rouhani, et al.
Best Practice & Research Clinical Haematology (2025), pp. 101625-101625
Closed Access
Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid
Jianglin Wang, Xin Hu, Wei Jiang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 9
Jianglin Wang, Xin Hu, Wei Jiang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 9
Comorbidity in bullous pemphigoid: up-date and clinical implications
Johanna Huttelmaier, Sandrine Benoit, Matthias Goebeler
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Johanna Huttelmaier, Sandrine Benoit, Matthias Goebeler
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction
Ting Cao, Xuyang Zhou, Xingbiao Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Ting Cao, Xuyang Zhou, Xingbiao Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid
Belén de Nicolás-Ruanes, Asunción Ballester-Martinez, Emilio Garcia‐Mouronte, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 16786-16786
Open Access | Times Cited: 9
Belén de Nicolás-Ruanes, Asunción Ballester-Martinez, Emilio Garcia‐Mouronte, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 16786-16786
Open Access | Times Cited: 9
A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy
Shasha Guan, Linlin Zhang, Junyan Zhang, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 7
Shasha Guan, Linlin Zhang, Junyan Zhang, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 7
Successful treatment of checkpoint inhibitor‐associated bullous pemphigoid with dupilumab in a patient with angiosarcoma
Inga Hansen, Christoffer Gebhardt, Nina Booken, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2024) Vol. 22, Iss. 4, pp. 587-589
Open Access | Times Cited: 2
Inga Hansen, Christoffer Gebhardt, Nina Booken, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2024) Vol. 22, Iss. 4, pp. 587-589
Open Access | Times Cited: 2
A Case of Bullous Pemphigoid with Significant Infiltration of CD4-Positive T Cells during Treatment with Pembrolizumab, Accompanied by Pembrolizumab-Induced Multi-Organ Dysfunction
Yoshihito Mima, Tsutomu Ohtsuka, Ippei Ebato, et al.
Diagnostics (2024) Vol. 14, Iss. 17, pp. 1958-1958
Open Access | Times Cited: 2
Yoshihito Mima, Tsutomu Ohtsuka, Ippei Ebato, et al.
Diagnostics (2024) Vol. 14, Iss. 17, pp. 1958-1958
Open Access | Times Cited: 2
Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer
Ting Wang, Qianwen Shao, Chunmei Xiao, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
Ting Wang, Qianwen Shao, Chunmei Xiao, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
Review of T Helper 2-Type Inflammatory Diseases Following Immune Checkpoint Inhibitor Treatment
Yoshihito Mima, Tsutomu Ohtsuka, Ippei Ebato, et al.
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1886-1886
Open Access | Times Cited: 1
Yoshihito Mima, Tsutomu Ohtsuka, Ippei Ebato, et al.
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1886-1886
Open Access | Times Cited: 1
Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitor
Yingyue Zhang, Xianwei Cao, Jianbo Tong
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Yingyue Zhang, Xianwei Cao, Jianbo Tong
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
